ProMIS neurosciences raises $0.8 million in registered direct offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025 7:00 AM EDTCAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- Â ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemers disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinsons disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor.
The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the Pre-Funded Warrants) to purchase 984,736 common shares, no par value (the Common Shares). The... More
